Market Segmentation:
- By Disease Type
- Large vessel vasculitis
- Medium vessel vasculitis
- Small vessel vasculitis
- Variable vessel vasculitis
- Single organ vasculitis
- Others
- By Drug Class
- Corticosteroids
- Immunosuppressants
- NSAIDs
- Biologics
- Interleukin inhibitors
- Integrin inhibitors
- Others
- By Route of Administration
- Oral
- Injectable
- Intravenous
- Topical
- Inhalation
- Others
- By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Clinics & infusion centers
- Others
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The Vasculitis market was valued at USD 4.5 billion in 2023.
Rising prevalence of autoimmune disorders, Improving diagnosis and treatment, Emerging biologics and targeted therapies, Higher research and development
Lack of complete cure, High cost of biologics, Diagnosis challenges due to overlapping symptoms, Adverse effects of immunosuppressants
The small vessel vasculitis segment accounts for the largest share in the Vasculitis market.
GlaxoSmithKline, Genentech, ChemoCentryx, Kiniksa Pharmaceuticals, Takeda Pharmaceuticals, and AstraZeneca.
The Vasculitis market is projected to reach USD 7.2 billion by 2031 expanding at a CAGR of 6.3% during the forecast period of 2023-2031.